The U.S. Food and Drug Administration (FDA) approved Zanubrutinib on November 14, 2019.

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above.

The U.S. Food and Drug Administration (FDA) approved Cefiderocol on November 14, 2019, for the treatment of complicated urinary tract infections (cUTIs) and hospital-acquired bacterial pneumonia (HABP), including ventilator-associated bacterial pneumonia (VABP).

The improved version of CAR-T therapy, CAR-NK therapy, has recently attracted considerable attention from the academic and pharmaceutical sectors due to its increased tumor-specific targeting and cytotoxicity, cost-effectiveness and easier availability of NK cells, shorter large-scale production cycles, and enhanced efficacy in treating solid tumors.

The U.S. Food and Drug Administration (FDA) approved Reblozyl on November 8, 2019, for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

On June 12, Helsinn Healthcare announced the renewal of its distribution and licensing agreement with Chugai Pharma Europe to promote AKYNZEO® (a combination drug containing netupitant and palonosetron) in the UK and Ireland.

Jun 25th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

FDA Greenlights Merck’s KEYTRUDA® (pembrolizumab) Combined with Carboplatin and Paclitaxel for Treating Adults with Advanced or Recurrent Endometrial Cancer.

The U.S. Food and Drug Administration (FDA) approved diroximel fumarate, marketed under the brand name Vumerity, on October 29, 2019.

Marea Therapeutics, a biotechnology enterprise focused on clinical-stage developments and backed by Third Rock Ventures, is dedicated to creating innovative treatments for cardiometabolic disorders.

Trikafta, a combination of elexacaftor, ivacaftor, and tezacaftor, was approved by the U.S. Food and Drug Administration (FDA) on October 21, 2019.

Day One Enhances Pipeline with Innovative Clinical-Stage ADC Targeting PTK7 for Solid Tumors in Adults and Children.